Sociedad Americana de Hirudoterapia

Successful results with the use of a new reconstruction material for soft tissue defects of the lower extremity: neurocutaneous flaps

Research article published in Ulusal travma ve acil cerrahi dergisi = Turkish journal of trauma & emergency surgery : TJTES (2004)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportEnsayos clínicosGiderolu K et al. · Ulusal travma ve acil cerrahi dergisi = Turkish journal of trauma & emergency surgery : TJTES, 2004

Abstract

BACKGROUND: We evaluated the use of distally based neurocutaneous flaps in the reconstruction of soft tissue defects in the lower extremity caused by trauma or other reasons. METHODS: Sixty-six patients (49 males, 17 females; mean age 42 years; range 16 to 75 years) underwent reconstruction of lower extremity soft tissue defects with the use of neurocutaneous flaps. The defects were in the external (n=11) and internal malleolus (n=10), Achilles tendon (n=6), heel (n=11), foot (n=7), distal (n=9) and middle (n=7) third of the anterior tibia, the mid-plantar region (n=3), and the popliteal region (n=2). Sural and saphenous neurocutaneous flaps were used in 34 and 32 patients, respectively. The mean flap area was 135 square centimetres (range 54 to 286). The mean follow-up period was 32 months (range 11 to 58 months). RESULTS: Of sixty-six patients treated with neurocutaneous flaps, complete survival was achieved in 57 flaps (86.4%). Partial necrosis was encountered in six patients (9%). Total flap loss occurred in three patients (4.6%) who had diabetes, hypertension, and electrical burns, respectively. The most common complication during the postoperative period was venous congestion seen in 14 patients (21%), the majority of whom had diabetes (n=5), hypertension (n=3), and electrical burns (n=3), predisposing them to microcirculation disorders. This complication was successfully managed by leech therapy in 78.6%. CONCLUSION: Neurocutaneous flaps offer maximum reconstruction capacity with minimum donor site morbidity, making them a successful alternative in the treatment of soft tissue defects of the lower extremity in recent years.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeEnglish AbstractJournal Article
Indexed MeSH termsAdolescentAdultAgedFemaleHumansLeg InjuriesMaleMiddle AgedNecrosisPostoperative ComplicationsPlastic Surgery ProceduresRetrospective Studies

Resumen

We evaluated the use of distally based neurocutaneous flaps in the reconstruction of soft tissue defects in the lower extremity caused by trauma or other reasons.

Por qué esto importa para la hirudoterapia

This clinical study evaluated 66 patients who underwent lower-extremity reconstruction with distally based neurocutaneous flaps. The most common postoperative complication was venous congestion, occurring in 21% of patients, which was successfully managed by leech therapy in 78.6% of these cases. This finding provides clinical evidence that leech therapy was used effectively as a salvage measure for venous congestion in this specific reconstructive surgery series. The primary limitation is that leech therapy was a secondary outcome, with the abstract providing no details on the leech species, protocol, duration, or comparative outcomes against other treatments.

Citación

Successful results with the use of a new reconstruction material for soft tissue defects of the lower extremity: neurocutaneous flaps

Giderolu K et al. · Ulusal travma ve acil cerrahi dergisi = Turkish journal of trauma & emergency surgery : TJTES, 2004

Contexto clínico relacionado

Explore cómo esta investigación se conecta con la práctica clínica

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.